PR
TARS icon

PSP Research’s Tarsus Pharmaceuticals TARS Stock Holding History

PSP Research’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$441K Hold
7,000
– – 0.23% 29
2026
Q1 		$491K Buy
7,000
+481
+7% +$33.6K 0.35% 18
2025
Q4 		$534K Buy
+6,519
New +$487K 0.47% 37

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PSP Research's TARS Position: Q2 2026 in Review

PSP Research held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 7,000 shares worth $441K. The position accounts for 0.23% of the portfolio, ranked #29.

PSP Research first reported a position in TARS in Q4 2025 and has held it in 3 quarters since. The position peaked at $534K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • PSP Research held 7,000 shares of Tarsus Pharmaceuticals worth $441K as of Q2 2026.
  • PSP Research left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up 0.23% of PSP Research's portfolio in Q2 2026, its #29 holding.
  • PSP Research first reported a position in Tarsus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Tarsus Pharmaceuticals position peaked at $534K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.